This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vukanovic, J. Articles by Isaacs, J. T. Search for Related Content PubMed PubMed Citation Articles by Vukanovic, J. Articles by Isaacs, J. T.

Linomide Inhibits Angiogenesis, Growth, Metastasis, and Macrophage Infiltration within Rat Prostatic Cancers¹

Johns Hopkins Oncology Center [J. V., J. T. I.] and the Department of Urology [J. T. I.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Linomide, a quinoline-3-carboxamide, has the ability to inhibit the growth of prostatic cancer in vivo but not in vitro (T. Ichikawa et al., Cancer Res., 52: 3022–3028, 1992). The reason for this discrepancy is that linomide inhibits tumor growth not directly but indirectly in vivo via its ability to inhibit the angiogenic response induced within the growing prostatic cancer (J. Vukanovic, et al., Cancer Res., 53: 1833–1837, 1993). Tumor associated macrophages can stimulate angiogenesis via their ability to secrete various cytokines, particularly tumor necrosis factor (TNF-). Treatment of rats with linomide decreases significantly (P < 0.05), by more than 50%, the number of tumor associated macrophages within both locally invasive (i.e., from 20–40 to 10 macrophages/high power field) and highly metastatic primary prostatic cancers (i.e., from 60–70 to 15–37 macrophages/high power field). Monocytes/macrophages isolated from linomide treated rats had a decreased ability to secrete TNF- when challenged in vitro with the bacterial endotoxin, lipopolysaccharide [i.e., 702 ± 76 (SEM) ng of TNF-/10⁵ monocytes/macrophages from control versus 401 ± 2 ng of TNF-/10⁵ monocytes/macrophages from linomide treated rats]. In addition, when rats were treated with linomide and than challenged with lipopolysaccharide in vivo, the resulting elevation in serum TNF- was inhibited by 50% (i.e., 4.56 ± 1.8 ng/ml of TNF- in control versus 2.9–2.2 ng/ml depending upon the dose of linomide). The ability of linomide to decrease monocyte/macrophage secretion of TNF- is not immediate, however, since the secretion of TNF- induced by lipopolysaccharide challenge of monocytes/macrophages isolated from untreated animals is not decreased by acute (i.e., <4 h) linomide treatment in vitro. These results demonstrate that the ability of linomide to inhibit the secretion of TNF- by monocytes/macrophages requires either additional time or host factors. To test if natural killer (NK) cells might be one of the additional host factors required for the in vivo abilities of linomide, prostatic cancer bearing rats were treated with appropriate antiserum to deplete NK cells and then tested for their response to linomide treatment. These studies demonstrated that the antitumor, antimetastatic, and antimacrophage effects of linomide were unaffected by NK cell depletion. Thus, the antiangiogenic effect of linomide is NK independent and is associated with inhibition of tumor associated macrophage number and their ability to secrete TNF-.

¹ Supported by NIH Grant CA62482.

² To whom requests for reprints should be addressed, at The Johns Hopkins Oncology Center, 422 N. Bond Street, Baltimore, MD 21231.

Received 9/ 8/94. Accepted 2/21/95.

This article has been cited by other articles:

				F. Zhang, W. Lu, and Z. Dong Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951. [Abstract] [Full Text] [PDF]

				M. C. A. Duyndam, M. C. G. W. Hilhorst, H. M. M. Schluper, H. M. W. Verheul, P. J. van Diest, G. Kraal, H. M. Pinedo, and E. Boven Vascular Endothelial Growth Factor-165 Overexpression Stimulates Angiogenesis and Induces Cyst Formation and Macrophage Infiltration in Human Ovarian Cancer Xenografts Am. J. Pathol., February 1, 2002; 160(2): 537 - 548. [Abstract] [Full Text] [PDF]

				J. H. Noseworthy, J. S. Wolinsky, F. D. Lublin, J. N. Whitaker, A. Linde, P. Gjorstrup, and H. C. Sullivan Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results Neurology, May 9, 2000; 54(9): 1726 - 1733. [Abstract] [Full Text] [PDF]

				D. L. Livant, R. K. Brabec, K. J. Pienta, D. L. Allen, K. Kurachi, S. Markwart, and A. Upadhyaya Anti-invasive, Antitumorigenic, and Antimetastatic Activities of the PHSCN Sequence in Prostate Carcinoma Cancer Res., January 1, 2000; 60(2): 309 - 320. [Abstract] [Full Text]

				D. J. Gross, I. Reibstein, L. Weiss, S. Slavin, I. Stein, M. Neeman, R. Abramovitch, and L. E. Benjamin The Antiangiogenic Agent Linomide Inhibits the Growth Rate of von Hippel-Lindau Paraganglioma Xenografts to Mice Clin. Cancer Res., November 1, 1999; 5(11): 3669 - 3675. [Abstract] [Full Text] [PDF]

				M. Toi, T. Ueno, H. Matsumoto, H. Saji, N. Funata, M. Koike, and T. Tominaga Significance of Thymidine Phosphorylase as a Marker of Protumor Monocytes in Breast Cancer Clin. Cancer Res., May 1, 1999; 5(5): 1131 - 1137. [Abstract] [Full Text] [PDF]

				I. Franck-Lissbrant, S. Haggstrom, J.-E. Damber, and A. Bergh Testosterone Stimulates Angiogenesis and Vascular Regrowth in the Ventral Prostate in Castrated Adult Rats Endocrinology, February 1, 1998; 139(2): 451 - 456. [Abstract] [Full Text] [PDF]

				G. Zandman-Goddard, J. George, Y. Levy, M. Blank, S. Slavin, and Y. Shoenfeld Review : Modulation of experimental systemic lupus erythematosus with linomide Lupus, August 1, 1996; 5(4): 328 - 333. [Abstract] [PDF]